← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2025-05-30 08:00:00 | Alx Oncology To Present At The Jefferies 2025 Global Healthcare Conference South san francisco, calif., may 30, 2025 (globe newswire) -- alx oncology holdings inc., (’alx oncology’ or the ’company’) (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the jefferies 2025 global healthcare conference. details are as follows: |
| 2025-05-20 08:00:00 | Alx Oncology Highlights Differentiated Design, Preclinical Data And Development Plans For Egfr-targeted Adc, Alx2004, In R&d Webcast Event - a potential best- and first-in-class antibody-drug conjugate (adc) for the treatment of egfr-expressing solid tumors, alx2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity |
| 2025-05-13 08:00:00 | Alx Oncology To Host R&d Webcast Event Highlighting Its Novel Egfr Targeting Antibody-drug Conjugate, Alx2004, On May 20, 2025 South san francisco, calif., may 13, 2025 (globe newswire) -- alx oncology holdings inc., (’alx oncology’ or the ’company’) (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on may 20, 2025, to provide an update on alx2004, the company’s potentially best- and first-in-class investigational antibody-drug conjugate (adc). the webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for alx2004 following clearance of the investigational new drug application from the u.s. food and drug administration earlier this year. |
| 2025-05-08 08:30:00 | Alx Oncology Reports First Quarter 2025 Financial Results And provides Corporate Update Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at r&d day in march, company is on track to initiate phase 2 aspen-breast and phase 1 aspen-crc studies in mid-2025 ind clearance received from u.s. fda for novel egfr-targeted antibody-drug conjugate (adc), alx2004, paving way for mid-year clinical program initiation; company to host webcast focused on alx2004 research program on may 20 company will not pursue u.s. registrational path in gastric cancer following receipt of fda feedback that accelerated approval pathway is not feasible based on aspen-06 due to standard-of-care evolving to enhertu® data milestones expected across company’s three clinical programs in 2026 cash runway has been extended into q4 2026 south san francisco, calif., may 08, 2025 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the first quarter ended march 31, 2025, and provided a corporate update. |
| 2025-05-05 08:58:00 | Alexander’s Announces First Quarter Financial Results Paramus, n.j., may 05, 2025 (globe newswire) -- alexander’s, inc. (new york stock exchange: alx) filed its form 10-q for the quarter ended march 31, 2025 today and reported: |
| 2025-05-02 08:00:00 |
|
| 2025-04-30 11:39:00 |
|
| 2025-04-25 13:10:00 |
|
| 2025-04-25 09:00:00 |
|
| 2025-04-24 12:13:00 |
|
| 2025-03-06 16:01:00 |
|
| 2025-03-05 08:00:00 |
|
| 2025-02-27 08:00:00 |
|
| 2025-02-18 08:00:00 |
|
| 2025-02-10 09:15:00 |
|
📰 Browse additional press releases for Alexanders REIT!
Sign up for free or log in✍️ Sign up to get "The Checklist Value Investor — A Smarter Way to Pick Stocks" for free